Advanced Solid Tumors
Conditions
Keywords
tumor, cancer, phase1, TKI258
Brief summary
The purpose of in this study is to assess the safety profile and estimate the maximum tolerated dose of TKI258 in Japanese patients.
Interventions
DRUGTKI258
Sponsors
Novartis Pharmaceuticals
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Written informed consent must be obtained prior to any screening procedures * Advanced solid tumors * Agreement to remaining hospitalized * ECOG performance status of 0 or 1 * Life expectancy of at least 3 months * Pregnant women. Male and female patients of reproductive potential must agree to employ an effective method of birth control * Demonstrate the specific hematological /blood chemistry laboratory values
Exclusion criteria
* Receipt of any investigational compound within 28 days prior to the first dose of study drug or failure to have recovered from the side effects of such prior therapy * Receipt of other antineoplastic therapy, including chemo-, hormonal, immuno-, and radiation therapy, within 28 days (with some exceptions) * Patients with CNS and/or leptomeningeal disease metastases * Presence or history of thromboembolic or cerebrovascular events * Impaired cardiac function or clinically significant cardiac disease * Malabsorption syndrome or uncontrolled gastrointestinal toxicities * Patients known to be HIV- or HBV- or HCV- positive * Patients with acute or chronic uncontrolled infection * Patients who have undergone surgery with general anesthesia for any cause within 28 days prior to the first dose of study drug * Patients who have been receiving anticoagulant therapy * Receipt of any hematopoietic colony stimulating factor or blood transfusion within 14 days prior to the first dose of study drug * Patients who have been administering concomitant medication which may prolong the QTc interval * Patients with interstitial pneumonia or pulmonary fibrosis proven on a chest CT scan * Patients with a large volume of ascitic and/or pleural fluid which requires drainage * Patients with any bone fractures * Deemed otherwise unsuitable by the investigator Other protocol-defined inclusion/
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Maximum tolerated dose (MTD) of TKI258 | 30 days |
Secondary
| Measure | Time frame |
|---|---|
| Antineoplastic activity based on the RECIST criteria | 22 months |
Countries
Japan
Outcome results
None listed